Testing modalities for ALK-driven lung cancer: A narrative review

Testing modalities for ALK-driven lung cancer: A narrative review

Anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC) comprises a distinct molecular entity with a reported global prevalence of 5–7%. The development and rapid approvals of small molecule ALK tyrosine kinase inhibitors (TKIs) have led to the development of diagnostic strate...

Full description

Bibliographic Details
Main Authors: Shrinidhi Nathany, Mansi Sharma, Ullas Batra
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Cancer Research, Statistics, and Treatment
Subjects:
carcinoma
eml4-alk
fluorescence
in situ hybridization
next-generation sequencing
non-small cell lung
nsclc
Online Access:http://www.crstonline.com/article.asp?issn=2590-3233;year=2023;volume=6;issue=3;spage=432;epage=439;aulast=Nathany

Internet

http://www.crstonline.com/article.asp?issn=2590-3233;year=2023;volume=6;issue=3;spage=432;epage=439;aulast=Nathany

Similar Items